Asthma phenotyping has already been implemented in daily clinical practice, with treatment choices (e.g., use of biologics in severe asthma patients) being based on validated biomarkers linked to type 2 classification status (e.g., eosinophil counts, exhaled breath nitric oxide levels) and allergy (e.g., IgE antibody levels) [25]. This evidence concerns the gene IGHE and asthma.